Your session is about to expire
← Back to Search
Capecitabine for Triple-Negative Breast Cancer
Study Summary
This trial is testing whether a liquid biopsy can help identify which triple-negative breast cancer patients will benefit from capecitabine treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 & 3 trial • 151 Patients • NCT03093870Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am HIV positive or have active hepatitis B or C.I have not had surgery to completely remove my cancer.You have taken any experimental drugs within 4 weeks before the study starts.My side effects from previous cancer treatments are mild, except for hair loss and some nerve pain.My cancer has not spread to other parts of my body.I am a woman who can have children and I have a negative pregnancy test.I have not finished my planned radiation therapy.I cannot swallow pills.It has been at least 4 weeks since my last chemotherapy session.My blood tests show normal white blood cell and platelet counts.My breast cancer was stage I-III and triple-negative at diagnosis.My breast cancer has spread to other parts of my body.I am 18 years old or older.I am scheduled for 6 months or 8 cycles of capecitabine treatment.My kidney function is within the normal range.My cancer is mostly not driven by estrogen or progesterone.I still have cancer after 4 rounds of initial chemotherapy.My liver tests are within the normal range, or slightly above if I have Gilbert's syndrome.I can take care of myself and am up and about more than half of my waking hours.I am willing to use birth control during and for 3 months after the study.I can sign the consent form and follow the study's requirements.
Frequently Asked Questions
To what maladies is Capecitabine typically administered?
"Capecitabine is regularly employed to combat malignant neoplasms. It has been found useful against pancreatic endocrine carcinoma, colorectal carcinoma, and refractory ovarian cancer as well."
Has the Federal Drug Administration granted its stamp of approval to Capecitabine?
"Our team at Power has ascribed a score of 2 to Capecitabine as this Phase 2 trial only displays data validating the therapy's safety but not its efficacy."
Can you provide an overview of the research conducted using Capecitabine?
"At present, there are 334 ongoing studies of Capecitabine with 126 trials in Phase 3. Of those investigations, the majority take place near Woolloongabba, Queensland; however, research sites for this drug can be found across 12828 locations worldwide."
Are there any vacancies remaining in this clinical trial?
"The trial is currently recruiting participants, as evidenced by the clinicaltrials.gov listing. It was first made available on February 3rd 2021 and was most recently amended on January 7th 2022."
What is the cap on participation in this research endeavor?
"Affirmative. Clinicaltrial.gov verifies that this clinical trial, first unveiled on February 3rd 2021, is still actively recruiting participants. As part of the study, 25 test subjects need to be sourced from a single medical facility."
Share this study with friends
Copy Link
Messenger